INVA:NSD-Innoviva Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 19.36

Change

0.00 (0.00)%

Market Cap

USD 1.24B

Volume

1.81M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.16B
ARGX argenx NV ADR

N/A

USD 32.02B
MRNA Moderna Inc

N/A

USD 26.25B
BGNE BeiGene Ltd

N/A

USD 22.45B
SMMT Summit Therapeutics PLC

N/A

USD 17.92B
RPRX Royalty Pharma Plc

N/A

USD 16.34B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 16.16B
UTHR United Therapeutics Corporatio..

N/A

USD 15.09B

ETFs Containing INVA

CGV Two Roads Shared Trust 1.43 % 0.00 %

N/A

USD 0.10B
MYLD 1.21 % 0.00 %

N/A

N/A
FYT First Trust Small Cap Val.. 0.71 % 0.70 %

N/A

USD 0.17B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.70% 72% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.70% 72% C 79% B-
Trailing 12 Months  
Capital Gain 50.08% 74% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.08% 74% C 84% B
Trailing 5 Years  
Capital Gain 78.27% 82% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.27% 82% B 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.65% 65% D 64% D
Dividend Return 8.65% 65% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.81% 88% B+ 63% D
Risk Adjusted Return 30.03% 84% B 63% D
Market Capitalization 1.24B 82% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.